PAC Cardio-1 B3
Contenido
REFERENCIAS
EL SÍNDROME DE ANGINA INESTABLE
  1. Alison HW, Russell RO, Mantle JA et al. Coronary anatomy and arteriography in patients with unstable angina pectoris. Am J Cardiol 1978;41: 204.
  2. Ambrose JA, Hjemdahl-Mosen CE, Gorlin R et al. Angiographic demonstration of a common link between unstable angina pectoris and non-Q wave acute myocardial infarction. Am J Cardiol 1988;61: 244.
  3. McMahon MM, Brown BG, Cukinngnan R et al. Quantitative coronary angiography: Measurement of the critical stenosis in patients with unstable angina and single vessel disease without collaterals. Circulation 1979;60: 106.
  4. Braunwald E, Jones RH, Mark DB et al. Diagnosis and managing unstable angina. Circulation 1994;90: 613.

  5. Capone G, Wolf NM, Meyer B et al. Frequency of intracoronary filling defects by angiography in angina pectoris at rest. J Am Coll Cardiol 1985;56: 403.

  6. Sherman CT, Litvack F, Grundfest W et al. Coronary angioscopy in patients with unstable angina pectoris. N Engl J Med 1986;315: 913.

  7. Fitzgerald DJ, Catella F, Fitzgerald GA. Platelet activation in unstable coronary disease. N Engl J Med 1986;315: 983.

  8. Alexopolus D, Ambrose JA, Stump D et al. Thrombosis-related markers in unstable angina pectoris. J Am Coll Cardiol 1991;17: 866.

  9. Théroux P, Outment H, La Tour JG et al. Aspirin, heparin or both to treat acute unstable angina. N Engl J Med 1988;319: 1105.

  10. Kaul S, Abbot RD. Evaluation of chest pain in the emergency department. Ann Intern Med 1994;121: 976.

  11. Peels CH, Visser Ca, Funke KA et al. Usefulness of two-dimensional echocardiography for inmediate detection of myocardial ischemia in the emergency room. Am J Cardiol 1990;65: 687.

  12. Wackers FJT, Lie KI, Liem Kl et al. Potential value of thallium-201 scintigraphy as a means of selecting patients for the coronary care unit. Br Med J 1979;41: 111.

  13. Curfman GD, Heinsimer JA, Lozner E C et al. Intravenous nitroglycerin in the treatment of spontaneous angina pectoris: a prospective, randomized trial. Circulation 1983;67: 276.

  14. Parker JO, Farrel B, Lakey KA et al. Effect of intervals between doses on the development of tolerance to isorbid dinitrate. N Engl J Med 1987;316: 1440.

  15. Thadani U, Whitsett T, Hamilton SF. Nitrate therapy for myocardial ischemic syndromes: current perpective including tolerance. Curr Probl Cardiol 1988;13: 725.

  16. Gottlieb SO, Weisfeldt ML, Ouyang P et al. Effects of the addition of propranolol to theraphy with nifedipine for unstable angina pectoris. A randomized, double-blind, placebo-controlled trial. Circulation 1986;73: 331.

  17. Muller JE, Turi ZG, Pearle DL et al. Nifedipine and conventional therapy for unstable angina pectoris: A randomized, double-blind comparison. Circulation 1984;69: 729.

  18. Report of the Holland Interuniversity Nifedipine-Metoprolol Trial (HINT) research group. Early treatment of unstable angina in the coronary care unit: A randomized, double blind, placebo controlled comparison of recurrent ischaemia in patients with nifedipine or metoprolol or both. Brit Heart J 1986;56: 400.

  19. Tiltmant PY, LaBlance JM, Thieuleux FA et al. Detrimental effect of propranolol in patients with coronary arterial spasm countered by combination with diltiazem. Am J Cardiol 1983;52: 230.

  20. Théroux P, Waters D, Qui S et al. Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina. Circulation 1993;88: 2045.

  21. RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990;336: 827.

  22. TIMI III A Investigators. Early effects of tissue-type plasmogen activator added to conventional therapy on the culprit coronary lesion in patients presenting with ischemic cardiac pain at rest. Circulation 1993;87: 38.
    2
  23. TIMI III B Investigators. Effects of tissue plasmogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q wave infarction: results of the TIMI III B trial. Circulation 1994;89: 1545.

  24. Lukas MA, Deutsch E, Laskey WK. Beneficial effect of heparin therapy on PTCA outcome in unstable angina. Am J Cardiol 1988;11: 132 A.

  25. Meyer JH, Rupprecht R, Kottmeyer BM et al. Coronary angioplasty in unstable angina. En: Unstable angina. Berlin Heidelberg: Springer-Verlag, 1990:235.

  26. RITA Trial Participants. Coronary angioplasty versus coronary artery bypass surgery: The Randomized Intervention Treatment of Angina (RITA) Trial. Lancet 1993;341: 573.

  27. Pryor DB, Shaw L, McCantns CB et al. Value of the history and physical in identifying patients at increased risk for coronary artery disease. Ann Intern Med 1993;118: 81.

  28. Russell RO, Moraski RE, Kouchoukos N et al. Unstable angina pectoris: national cooperative study to compare surgical and medical therapy. Am J Cardiol 1978;42: 839.

  29. Scott SM, Luchi RJ, Deupree RH. Veterans Administration Cooperative Study for treatment of patients with unstable angina: results in patients with abnormal left ventricular function. Circulation 1988;78 (sup I): 113.

  30. Sharma GV, Deupree RH, Khuri SF et al. Coronary bypass surgery improves survival in high-risk unstable angina: results of a Veterans Administration Unstable Angina Cooperatyive Study Group. Circulation 1991;84 (Sup III): 260.

  31. Ringovist I, Fisher LD, Davis KB et al.Prognostic value of angiographic indices of coronary artery disease from the coronary artery surgery study (CASS). J Clin Invest 71: 1854,1983.

  32. Detre K, Peduzzi P, Murphy M et al. Effect of bypass surgery on survival in patients in low- and high - risk subgroups deliniated by the use of simple clinical variables. Circulation 1981;63: 1329.

  33. Rahimtoola SH, Nunley D, Grunkemeier G et al. Ten year survival after coronary bypass surgery for unstable angina. N Engl J Med 1983;308: 676.

  34. Rahimtoola SH, Fessler CL, Grunkemeier GL y Starr A. Fifteen-year survival after coronary bypass surgery for unstable angina. Coronary Artery Dis 1990;1: 323.

  35. Topol EJ, Fuster V, Harrington RA, et al. Recombinant hirudin for unstable angina pectoris. A multicenter, randomized angiographic trial. Circulation 1994;89: 1557.

  36. Schulman SP, Goldschmith-Clermont JP, Navetta F, et al. Inegrelin in unstable angina: a double blind randomized trial. Circulation 1993;88: 3272.

  37. Balsano F, Rizzon P, Violi F, et al. Antiplatelet treatment with ticlopidine in unstable angina. A controlled multicenter trial. Circulation 1990;82: 17.

  38. Cohen M.Platelet glicoprotein IIb-IIIa receptor inhibitors in coronary artery disease. Ann Intern Med 1996;124: 843.

TRATAMIENTO DEL INFARTO AGUDO DEL MIOCARDIO
  1. Daimond MA. Milestones in the treatment of acute myocardial infarction. Clin Cardiol 1994;17(Suppl. Y):1-3-1-6.
  2. Brown KWG, MacMillan RL, Forbarth N. Coronary unit: an intensive care center for acute myocardial infarction. Lancet 1963;2:349-352.

  3. Forrester JS, Diamond GA, Swan HJC. Correlative classification of clinical and hemodynamic funtion after myocardial infarction. Am J Cardiol 1977;39:2;137-145.

  4. DeWood MA, Spores J, Nostke R. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980;303:897-902.

  5. Grupo Italiano per lo studio della streptochinasi nell’infarto miocardico (GISSI). Longterm effects of intravenous thrombolysis in acute myocardial infarction: final report of the GISSI study. Lancet 1987;2:871-874.

  6. The International Study Group. In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin. Lancet 1990;336:71-75.

  7. The TIMI Study Group. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction Results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II Trial. N Engl J Med 1989;320:618-627.

  8. Wilcox RG, von der Lippe G, Olsson CG, Jensen G, Skene AM, Hampton JR. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction. Anglo-Scandinavian Study of Early Thrombolysis (ASSET). Lancet 1988;2:525-530.

  9. AIMS Trial Study Group. Long-term effects of intravenous anistreplase in acute myocardial infarction: final report of the AIMS study. Lancet 1990;335:427-431.

  10. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;2:349-360.

  11. Sobel BE, Braunwald E. The management of acute myocardial infartion En: Braunwald E, ed. Heart disease. A textbook of Cardiovascular Medicine. Ed. Saunders Company, 1984:1301-1333.

  12. The GUSTO Investigators: An International randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673-682.

  13. Gibbons RJ, Holmes DR, Reeder GS, Baley KR, Hpfenspirger MR, Gersh BJ. Immediate angioplasty compared with the administration of a thrombolytic agent followed by conservative treatment for myocardial infarction: The Mayo Coronary Care Unit and Catheterization Laboratory Groups. N Engl J Med 1993;328:685-691.

  14. Grines CL, Browne KF, Marco J. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction: the Primary Angioplasty in Myocardial Infarction Study Group. N Engl J Med 1993;328:673-679.

  15. O’Keeffe JH, Rutherford BD, McConahay DR. Early and late results of coronary angioplasty without antecedent thrombolytic therapy for acute myocardial infarction. Am J Cardiol 1989;64:1221-1230.

  16. O’Keefe JH, Rutherford BD, McConahay DR. Myocardial salvage with direct coronary angioplasty for acute infarction. Am Heart J 1992;123:1-6.

  17. Reimer KA, Jennings RB. The wavefront phenomenon of myocardial ischemia cell death. II. Transmural progression of necrosis within the frame work of ischemic bed size (myocardium at risk) and collateral flow. Lab Invest 1979;40:633-644.

  18. Lupi E. Tratamiento del infarto agudo del miocardio: trombolisis y angioplastia directa. Rev Fed Arg Cardiol 1996;25:429-434.

  19. Libby P. Molecular bases of the acute coronary syndrome. Circulation 1995;91:2844-2850.

  20. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndrome. N Engl J Med 1992;326:242-250.

  21. Loner RA, Shook T, Przyklenk K. for the TIMI 4 Investigators: previous angina alters inhospital outcome in TIMI 4: a clinical correlate to preconditioning? Circulation 1995;91:33-47.

  22. Ottini F, Galvani M, Ferrini D. Prodromal angina limits infarct size: a role for ischemic preconditioning. Circulation 1995;91:291-297.

  23. Habib GB, Heibig J, Forman SA. Influence of coronary collateral vessels on myocardial infarct size in humans. Circulation 1991;93:739-746.

  24. Granger C, Callif R, Toppol E. Thrombolytic therapy for acute myocardial infarction: a review. Drugs 1992;44:293-325.

  25. Yusuf S, Collins R, Peto R. Intravenous and intracoronary fribrinolytic therapy in acute myocardial infarction: overviewof results on mortality, reinfarction and side effects from 33 randomized controlled trial. Eur Heart J 1985;6:556-585.

  26. The I.S.A.M. Study Group. A prospective trial of intravenous streptokinase in acute myocardial infarction (I.S.A.M.). Mortality, morbidity, and infarct size at 21 days. N Engl J Med 1986;314:850-855.

  27. Simoons ML, Serruys PW, van den Brand M. Early thrombolysis in acute myocardial infarction: limitation of infarct size and improved survival. J Am Coll Cardiol 1986;7:717-728.

  28. Koren G, Weiss AT, Hasin Y. Prevention of myocardial damage in acute myocardial ischemia by early treatment with intravenous streptokinase. N Engl J Med 1985;313:1384-1389.

  29. Grupo Italiano Per Lo Studio Della Sopravivenza Nell’Infarto Miocardico. GISSI-2: a factorial randomized trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet1990;336:65-71.

  30. ISIS-3 (Third International Study of Infarct Survival)Collaborative Group. A randomized comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin alone among 41,299 cases of suspected acute myocardial infarction: ISIS-3. Lancet 1992;339:753-770.

  31. Ryan TH. ACC/AHA Guidelines for the Management of Patients With Acute Myocardial Infarction: a report of the American College of Cardiology/American Heart Association. Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol 1996;28:1328-1428.

  32. ACC/AHA Guidelines for the Management of Patients With Acute Myocardial Infarction: a report of the American College of Cardiology/American Heart Association. Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). Circulation 1996;94:23-41.

  33. Grines CL, De Maria AN. Optimal utilization of thombolytic therapy for acute myocardial infarction; concepts and controversies. J Am Coll Cardiol 1990;16:223-231.

  34. Gunnar RM, Bourdillon PDV, Dixon DW. Guidelines for the early management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Assesment of Diagnosis and Therapeutic Cardiovascular Procedures (Subcommitte to Develop Guidelines for the Early Management of Patients with Acute Myocardial Infarction). J Am Coll Cardiol 1990;16:249-252.

  35. Martínez C, Chuquiure E, Carrillo J, González H, Peña M, Lupi E. Trombolisis en el infarto agudo del miocardio de localización inferior con extensión eléctrica del ventrículo derecho. Experiencia en 156 casos. Arch Inst Cardiol Mex 1995;65(Abs)70.

  36. Martínez-Sánchez C, Verdejo J, Lorenzo A, Carrillo J, González H, Lupi-Herrera E. Trombolisis sistémica en el infarto agudo del miocardio en pacientes mayores de 70 años. Arch Inst Cardiol Mex 1991;61(Abs)54.

  37. Topol E. Trombolytic intervention. En: Textbook of Interventional Cardiology. Saunders Company, 1994;68-111.

  38. Martínez-Sánchez C, Chuquiure E, Martínez-Sánchez J, Lupi E. Tratamiento del infarto agudo del miocardio con rt-PA en 60 minutos. Estudio Cooperativo. Arch Inst Cardiol Mex 1997;67:126-131.

  39. Sherry S. Cardiovascular drug therapy. En: Messerly FH, ed. Saunders Company. 1990:1479.

  40. Tillet WS, Sherry S. The effect in patients of streptoccocal fibrinolysin (streptokinase) and streptoccocal desoxyrribonuclease on fibrinous, purulent and sanguineous pleural exudations. J Clin Invest 1949;28:173-181.

  41. Sawyer WD, Fletcher AP, Alkjaersig N. Studies on the thrombolytic activity of human plasma. J Clin Invest 1960;39:426-438.

  42. Rijken DC, Collen D. Purification and characterization of the plasminogen activator secreted by human melanoma cells in culture. J Biol Chem 1981;256:7035-7046.

  43. Relik-van Wely L, Visser RF, van der Pol J, Bartholomeuys Y, Couvee JE. Angiographically assessed coronary arterial patency and reocclusion in patients with acute myocardial infarction treated with anistreplas: Results of the Anistreplase Reocclusion Multicenter Study (ARMS). Am J Cardiol 1991;68:296-300.

  44. Lincoff AM, Topol EJ. The illusion of reperfusion: Does anyone achieve optimal reperfusion during acute myocardial infarction? Circulation 1993;87:1792-1805.

  45. Ellis SG, Topol EJ, George BS. Recurrent ischemia without warning: analysis of risk factors for in-hospital ischemic events following successful thrombolysis with intravenous tissue plasminogen activator. Circulation 1989;80:1159-1165.

  46. Gash AK, Spann JF, Sherry S. Factors influencing reocclusion after coronary thrombolysis for acute myocardial infarction. Am J Cardiol 1986;57:175-177.

  47. Harrison DG, Ferguson DW, Collins SM. Rethrombosis after reperfusion with streptokinase: Importance of geometry of residual lesions. Circulation 1984;69:991-999.

  48. Ohman EM, Califf RM, Topol EJ. Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. Circulation 1990;82:781-791.

  49. Bates ER. Infarct artery patency. En: Bates ED, ed. Thrombolysis and adjuntive therapy for acute myocardial infarction. Marcel Dekker, 1993:3-27

  50. Granger CB, Califf RM, Topol EJ. Thrombolytic therapy for acute myocardial infarction. Drugs 1992;44:293-325.

  51. Neuhaus K, Feuerer W, Jeep-Tebbe S. Improved thrombolysis with a modified dose regimen of recombinant tissue-type plasminogen activator. J Am Coll Cardiol 1989;14:1566-1569.

  52. Carney R, Brandt T, Daley P. increased efficacy of rt-PA by more rapid administration: the RAAMI trial. Circulation 1990;82III-538 (abstract).

  53. Von Essen R, Vogt A, Roth M, Reib M, Tebbe U, Neuhaus KL. Early patency of infarct-related vessel after accelerated infusion of 100 mg rt-PA as compared to 30 mg APSAC: results of the TAPS study. Eur Heart J 1991;12:30 (abstract).

  54. Wall TC, Topol EJ, George BS. The TAMI-7 trial of accelerated plasminogen activator dose regimens for coronary thrombolysis: preliminary data. Circulation 1990;82(Suppl III):III-538 (abstract)

  55. Chitoiu T, Orha I, Teodorescu C, Fluerasu A. Clinic of Internal Medicina and Cardiology, Emorgency Hospital, Bucharest, Romanía. The rapid infusion of streptokinase in patients with acute myocardial infarction is followed by a greater rate of coronary reperfusion as compared to the standard protocol. Eur Heart J 1996;17:202(abstract.)

  56. Anshelevich M, Ansherlevich I, Kochkaryov F. Riga “Bicur Cholim” Hospital, Riga LAT. Safety of a new accelerated streptokinase regimen in acute myocardial infartion. Eur Heart J 1996;17:203(abstract).

  57. Tebbe U. J Am Coll Cardiol 1995;26:365.

  58. Loscalzo J, Ezratty A. Newer antiplatelet agents in acute myocardial infarction. En: Bates ED, ed. Thrombolysis and adjuntive therapy for acute myocardial infarction. Marcel Dekker, 1993:199-219.

  59. O’Neill W, Erbel R, Laufer N. Coronary angioplasty therapy of cardiogenic shock complicating acute myocardial infarction. Circulation 1985;72:III-309 (abstract).

  60. O’Neill W, Timmis G, Bourdillon P. A prospective randomized clinical trial of intracoronary streptokinase versus coronary angioplasty therapy of acute myocardial infarction. N Engl J Med 1986;314:812-828.

  61. Zijlstra F, de Boer MJ, Hoorntje JC, Reiffers S, Reiber JH, Suryapranata H. A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction. N Engl J Med 1993;328:680-684.

  62. Hermann HC, Malosky SA, Guidera SA. Patient selection reduces thrombotic complications of emergent stenting for failed PTCA. Cathet Cardiovasc Diagn 1995;34:286-292.

  63. Topol EJ, Holmes DR, Rogers WJ. Coronary angiography after thrombolytic therapy for acute myocardial infarction. Ann Intern Med 1991;114:877-885.

  64. Hochman JS, Boland J, Sleeper LA, and the SHOCK Registry Investigators. Current spectrum of cardiogenic shock and effect of early revascularization on mortality: Results of an international registry. Circulation 1995;91:873-881.

  65. Simpfendorfer C, Belardi J, Bellamy G, Galan K, Franco I, Hollman J. Frecuency management, and follow-up of patientes with acute coronary occlusions after percutaneous transluminal angioplasty. Am J Cardiol 1987;59:267-275.

  66. Labovitz AJ. Mechanical complications of acute myocardial infarction. Cardiovasc Rev Rep 1984;5:948-954.

  67. Lange R, Cigarroa J, Hillis D. Thrombolysis or primary PTCA for acute myocardial infarction. ACC Educational Highlights. 1977; 12(3): 1-4.

  68. Every NR, Parsons LS, Hlatky M, Martin JS, Weaver WV. A comparison of thrombolytic therapy with primary coronary angioplasty for acute myocardial infarction. N Engl J Med 1996;335:1253-1260.

  69. GUSTO II-B. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 1997;336:1621-28.

  70. Late assessment of thrombolytic eficacy (LATE) study with alteplase 6-24 hours after onset of acute myocardial infarction. Lancet 1993;342:759-766.

  71. Kim CB, Braunwald E. Potential benefits of late reperfusion of infarcted myocardium. The open artery hypothesis. Circulation 1993;88:2426-2436.

  72. Bassand JP. Left ventricular remodelling after acute myocardial infarction - solved and unsolved issues. Eur Heart J 1995;16(suppl I):58-63.

  73. Hermosillo AG, Dorado M, Casanova JM, Ponce de León S, Cossio J, Kersenovich S, Colin L, Iturralde P. Influence of infarct-related artery patency on the indexes of parasympathetic activity and prevalence of late potentials in survivors of acute myocardial infarction. J Am Coll Cardiol 1993;22:695-706.

  74. Clarke R, Mayo G, Price P, FitzGerald GA. Preservation of systemic vascular prostacyclin despite maximal presystemic platelet cyclooxygenase inhibition by controled release low dose aspirin (abstr). Circulation 1990;82(suppl III): III-602.

  75. Balsano F, Risson P, Violi F. Antiplatelet treatment with ticlopidine in unstable angina. A controlled multicenter clinical trial. Circulation 1990;82:17-26.

  76. Loscalzo J, Ezratty A. Newer antiplatelet agents in acute myocardial infarction. En: Bater ED, ed. Thrombolysis and adjuntive therapy for acute myocardial infarction. Marcel Dekker, 1993:199-220.

  77. Cercek B, Lew AS, Hod H. Enhancement of thrombolysis with tissue-type plasminogen activator by pretreatment with heparin. Circulation 1986;74:683-599.

  78. O’Connor CM, Meese R, Carney R. A randomized trial of intravenous heparin in conjuntion with anistreplase (anisoylated plasminogen streptokinase activator complex) in acute myocardial infarction; the Duke University Clinical Cardiology Study (DUCCS). J Am Coll Cardiol. 1994;23:11-18.

  79. Zerpa C, Nara J, Peña M, Arce R, Martinez-Sánchez C. ¿Es útil la heparina intravenosa después de trombolisis con estreptoquinasa en el infarto agudo del miocardio? (abstr). Arch Inst Cardiol Mex 1995;65(suppl 5)-300.

  80. Stein B, Fuster V. Clinical pharmacology of platelet inhibitors. En: Thrombosis in cardiovascular disorders. Saunders Company, 1992:111.

  81. Flaherty JT, Becker LC, Bulkley BH, Weiss JL, Gerstenblith G, Kallman CH. A randomized prospective trial of intravenous nitroglycerin in patients with acute myocardial infarction. Circulation 1983;68:576-588.

  82. Jugdutt BI, Sussex BA, Warnica JW, Rossall RE. Persistent reduction in left vetricular asynergy in patients with acute myocardial infarction by intravenous infusion of nitroglycerin. Circulation 1983;68:1264-1273.

  83. Jugdutt BI, Warnica JW. Intravenous nitroglycerin therapy to limit myocardial infarct size, expansion and complications. Effect of timing, dosage and infarct location. Circulation 1988;78:906-919.

  84. Yusuf S, Collins R, MacMahon S, Peto S. Effect of intravenous nitrates on mortality in acute myocardial infarction: an overview of the randomized trials. Lancet 1988;1:1088-1092.

  85. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995;345:669-685.

  86. The MIAMI Trial Research Group. Metoprolol in acute myocardial infarction: patients population. Am J Cardiol 1985;56:1G-57G.

  87. Oral captopril versus placebo among 13,634 patients with suspected acute myocardial infarction: interim report from the Chinese Cardiac Study (CCS-1). Lancet 1995;345:686-687.

  88. Ambrosioni E, Broghi C, Magnani B. The effect of the angiotensin-converting-enzime inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction: the Survival of Myocardial Infarction: Long-Term Evaluation (SMILE) Study Investigators. N Engl J Med 1995;332:80-85.

  89. Sigurdsson A, Swedberg K. Left ventricular remodelling, neurohormonal activation and early treatment with enalapril (CONSENSUS II) following myocardial infarction. Eur Heart J 1994;15(suppl B):14-19

  90. Ball S, Hll A, Murray G. Angiotensin-converting enzime inhibitors after myocardial infarction: indications and timing. J Am J Cardiol 1995;25(suppl)42S-6S.

  91. Furbergh CD, Psaty BM, Mayer JV. Nifedipine: dose-related increasee in mortality in patients with coronary heart disease. Circulation. 1995;92:1326-1331.

  92. Antman EM, Lau J, Kupelnick B, Mosteller F, Chalmers TC. A comparison of results of meta-analyses of randomized control trials and recommendations of clinical experts: treatments for myocardial infarction. JAMA 1992;268:240-248.

  93. Buring JE, Glynn RJ, Hennekens CH. Calcium channel blockers and myocardial infarction: a hypothesis formulated but not yet tested. JAMA 1995;274:654-655.

  94. Arsenian MA. Magnesium and cardiovascular disease. Prog Cardiovasc Dis 1993;35:271-310.

  95. Opie L. Drugs for the heart. Charter digitalis another intropics. W.B. Saunders, 1991.

  96. Gorlin R, Garg R. The effect of digitalis on morbidity and hospitalizations in patients with heart failure. Presented at the American College of Cardiology Annual Scientific Session; March 1996; Orlando, Fla.

  97. Campbell RWF. Arrhythmias. En: Julian DG, Braunwald E, ed. Management of acute myocardial infarction. London, England: WB Saunders Co, 1994:223.240.

  98. Lilavie CJ, Gersh PJ. Mechanical and electrical complication of acute myocardial infarction. Mayo Clin Proc 1990;65:709-730.

  99. Berger PB, Ruocco NA Jr, Ryan TJ, Frederick MM, Jacobs AK, Faxon DP. Incidence and prognostic implications of heart block complicating inferior myocardial infarction treated with thrombolytic therapy: results from TIMI-II. J Am Coll Cardiol 1988;12:589-594.

  100. Hindman MC, Wagner GS, JaRo M, Atkins JM, Scheinman MM, De Sanctis RW, Hutter AH Jr, Yeatman L, Rubenfire M, Pujura C, Rubin M, Morris JJ. The clinical significance of bundle branch block complication acute myocardial infarction, I: clinical characteristics, hospital mortality and one-year follow-up. Circulation 1978;58:679-688

  101. Antman EM. General hospital management. En: Julian DG, Braunwald E, ed. Management of acute myocardial infarction. London, England: WB Saunders Co, 1994:57-59.

  102. Ellis SG, Topol EJ, Gallison L, et al. Predictors of success for coronary angioplasty performed for acute myocardial infarction. J Am Coll Cardiol 1988;12:1407-1415.

  103. O’Keefe JH, Bayler L, Rutherford BD, Hartzler GO. Primary angioplasty for acute myocardial infarction in 1,000 consecutive patients: results in an unselected population and high-risk groups. Am J Cardiol 1993;72:107G-115G.

  104. Goldberg RJ, Gore JM, Alpert JS, et al. Cardiogenic shock after acute myocardial infarction: Incidence and mortality from a community-wide perspective, 1975 to 1988. N Engl J Med 1991;325:1117-1122.

  105. Ramhimtoola SH. The hibernating myocardium. Am Heart J 1989;117:211-221.

  106. Hochman J. Cardiogenic shock: Can we save the patient? ACC Educational Highlights. 1996;12(2):1-5.

  107. Cercek B, Shah P. Complicated acute myocardial infarction. Heart failure, shock, mechanical complications. Cardiology Clinics 1991;9(4):569-593.

  108. Lee L, Bates ER, Pitt B, et al. Percutaneous transluminal coronary angioplasty improves survival in acute myocardial infarction complicated by cardiogenic shock. Circulation 1988;78:1345.

  109. Isner JM, Roberts WC. Right ventricular infarction complicating left ventricular infarction. Am J Cardiol 1978;42:885.

  110. Goldstein JA, Vlahakes GJ, Verrier DE, et al. The role of right ventricular systolic dysfunction and elevated intrapericardial pressure in the genesis of low output in experimental right ventricular infarction. Circulation 1982;65:513-522.

  111. Kinch JW, Ryan TJ. Right ventricular infarction. N Engl J Med 1994;330:1211-1217.

  112. Martínez-Sánchez C, González H, Peña DM, Lupi E. Función del ventrículo derecho con y sin pericardio: modelo canino experimental. (abstract) Arch Inst Cardiol Mex 1995;65:120.

  113. Braunwald E. Unstable angina. A classification. Circulation 1980;61:759.

  114. Grande P. The Danish multicenter randomized study of invasive versus conservative treatment in patients with recurrent ischemia following thrombolysis in acute myocardial infarction: the Danis Acute Myocardial Infarction Trial (DANAMI). Lancet. In press.

  115. Hammerman H, Kloner RA, Schoen FJ, et al. Indomethacin-induced scar thinning after experimental myocardial infarction. Circulation 1983;67:1290-1295.

  116. Weisman H, Healy B. Expansion del infarto de miocardio, extension de infarto y reinfarto: conceptos fisiologicos. Sonnenblick E, Lesch M. En: Progress of cardiovascular disease. Coronary artery disease update. Coronary circulation. Buenos Aires: Editorial Panamericana, 1988.

  117. Mills NI, Everson CT, Hockmuth DR. Technical advances in the treatment of left ventricular aneurysm. Ann Thorac Surg 1993;55:792-800.

  118. Wei JY, Hutchins GM, Bulkley BH. Papillary muscle rupture in fatal acute myocardial infarction. Ann Intern Med 1979;90:1979.

  119. Nishimura RA, Schaff HV, Shuh C, et al. Papillary muscle rupture complicating acute myocardial infarction: Analysis of 17 patients. Am J Cardiol 1983;51:373.

  120. Skillington PD, Davies RH, Luff AJ, et al. Surgical treatment for infarct-related ventricular septal defects: improved early results combined with analysis of late functional status. J Thorac Cardiovasc Surg 1990;99:798-808.

  121. Gray RJ, Sethna D, Matloff JM. The role of cardiac surgery in acute myocardial infarction with mechanical complications. Am Heart J 1983;106:723.

  122. Rasmussen S, Leth A, Kjoller E, et al. Cardiac rupture in acute myocardial infarction: A review of 72 consecutive cases. Acta Med Scand 1979;11:205.

  123. Shelburne JC, Rubinstein D, Gorlin R. A reappraisal of papillary muscle dysfuntion: Correlative clinical and angiographic study. Am J Med 1969;46:862.
Contenido
Copyright © 2005 Dr. Scope. Derechos Reservados.
Diseño y Programación: Educación Médica Contínua